Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome

Article ID	Journal	Published Year	Pages	File Type
2849024	American Heart Journal	2008	8 Pages	PDF

Abstract

Among hypertriglyceridemic subjects with the metabolic syndrome, fenofibrate therapy reduced Lp-PLA2 mass, and these changes were associated with fewer small LDL-Ps.

Keywords

MCP-1 TMB VCAM-1 HDL-C MIP-1α IQR LysoPC PPARα LDL-C oxLDL ICAM-1 HRP LDL-P Fenofibrate Intervention and Event Lowering in Diabetes NF-κB nuclear magnetic resonance Lp-PLA2 tetramethylbenzidine NMR Field Platelet activating factor nuclear factor kappa B Lysophosphatidylcholine Oxidized low-density lipoprotein high-density lipoprotein cholesterol Low-density lipoprotein LDL interquartile ranges intercellular adhesion molecule-1 vascular cell adhesion molecule-1 horseradish-peroxidase Monocyte chemotactic protein-1 Macrophage inflammatory protein-1α Low-density lipoprotein cholesterol

Related Topics

Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine

Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome

Authors

Robert S. MD,